Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 11274

1.

Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study.

Cova E, Pandolfi L, Colombo M, Frangipane V, Inghilleri S, Morosini M, Mrakic-Sposta S, Moretti S, Monti M, Pignochino Y, Benvenuti S, Prosperi D, Stella G, Morbini P, Meloni F.

Int J Nanomedicine. 2019 Jan 23;14:773-785. doi: 10.2147/IJN.S186344. eCollection 2019.

2.

Actualités et perspectives concernant l’immunothérapie en oncologie thoracique.

Mignard X, Chaabane N, Fallet V, Wislez M.

Bull Cancer. 2018 Dec;105 Suppl 1:S16-S23. doi: 10.1016/S0007-4551(18)30386-2. Review. French.

PMID:
30595194
3.

Association between mesothelioma and non-occupational asbestos exposure: systematic review and meta-analysis.

Xu R, Barg FK, Emmett EA, Wiebe DJ, Hwang WT.

Environ Health. 2018 Dec 19;17(1):90. doi: 10.1186/s12940-018-0431-9.

4.

An unusual cause of acute surgical abdomen: benign multicystic peritoneal mesothelioma associated with adenomatous tumor.

Meşină C, Dumitrescu TV, Mogoantă SŞ, Ciorbagiu MC, Cristian DA, Meşină-Botoran MI, Gruia CL, Foarfă MC, Meşină M, Ciurea ME, Ciobanu D.

Rom J Morphol Embryol. 2018;59(3):971-976.

5.

Biodistribution and Tumor Uptake of 67Ga-Nimotuzumab in a Malignant Pleural Mesothelioma Xenograft.

Izquierdo-Sánchez V, Muñiz-Hernández S, Vázquez-Becerra H, Pacheco-Yepez J, Romero-Piña ME, Arrieta O, Medina LA.

Molecules. 2018 Nov 29;23(12). pii: E3138. doi: 10.3390/molecules23123138.

6.

Pleural Mesothelioma Detects by 18F-Choline PET/CT in a Patient With Biochemical Recurrence of Prostate Cancer.

Marco R, Guido F, Fernando DG, Laura E.

Clin Nucl Med. 2019 Feb;44(2):e116-e117. doi: 10.1097/RLU.0000000000002416.

PMID:
30516662
7.

Complex Immune Contextures Characterise Malignant Peritoneal Mesothelioma: Loss of Adaptive Immunological Signature in the More Aggressive Histological Types.

Tazzari M, Brich S, Tuccitto A, Bozzi F, Beretta V, Spagnuolo RD, Negri T, Stacchiotti S, Deraco M, Baratti D, Camisaschi C, Villa A, Vergani B, Rivoltini L, Pilotti S, Castelli C.

J Immunol Res. 2018 Oct 29;2018:5804230. doi: 10.1155/2018/5804230. eCollection 2018.

8.

Detection of circulating tumor cells with a novel microfluidic system in malignant pleural mesothelioma.

Yoneda K, Kuwata T, Chikaishi Y, Mori M, Kanayama M, Takenaka M, Oka S, Hirai A, Imanishi N, Kuroda K, Ichiki Y, Ohnaga T, Tanaka F.

Cancer Sci. 2019 Feb;110(2):726-733. doi: 10.1111/cas.13895. Epub 2019 Jan 8.

9.

Systematic review of quality of life following pleurectomy decortication and extrapleural pneumonectomy for malignant pleural mesothelioma.

Schwartz RM, Lieberman-Cribbin W, Wolf A, Flores RM, Taioli E.

BMC Cancer. 2018 Nov 29;18(1):1188. doi: 10.1186/s12885-018-5064-4. Review.

11.

Well differentiated papillary peritoneal mesothelioma treated by cytoreduction and hyperthermic intraperitoneal chemotherapy-the experience of the PSOGI registry.

Deraco M, Nizri E, Glehen O, Baratti D, Tuech JJ, Bereder JM, Kepenekian V, Kusamura S, Goere D.

Eur J Surg Oncol. 2019 Mar;45(3):371-375. doi: 10.1016/j.ejso.2018.10.065. Epub 2018 Oct 19.

PMID:
30473172
12.

Soluble AXL is ubiquitously present in malignant serous effusions.

Flem Karlsen K, McFadden E, Flørenes VA, Davidson B.

Gynecol Oncol. 2019 Feb;152(2):408-415. doi: 10.1016/j.ygyno.2018.11.012. Epub 2018 Nov 15.

PMID:
30448261
13.

Decrease in Intracellular Perforin Levels and IFN-γ Production in Human CD8+ T Cell Line following Long-Term Exposure to Asbestos Fibers.

Kumagai-Takei N, Nishimura Y, Matsuzaki H, Lee S, Yoshitome K, Otsuki T.

J Immunol Res. 2018 Oct 23;2018:4391731. doi: 10.1155/2018/4391731. eCollection 2018.

14.

Special Issue on Mechanisms of Mesothelioma Heterogeneity: Highlights and Open Questions.

Felley-Bosco E.

Int J Mol Sci. 2018 Nov 12;19(11). pii: E3560. doi: 10.3390/ijms19113560.

15.

Pyruvate Treatment Restores the Effectiveness of Chemotherapeutic Agents in Human Colon Adenocarcinoma and Pleural Mesothelioma Cells.

Mungo E, Bergandi L, Salaroglio IC, Doublier S.

Int J Mol Sci. 2018 Nov 10;19(11). pii: E3550. doi: 10.3390/ijms19113550.

16.

Establishment and characterization of CRISPR/Cas9-mediated NF2-/- human mesothelial cell line: Molecular insight into fibroblast growth factor receptor 2 in malignant pleural mesothelioma.

Wahiduzzaman M, Karnan S, Ota A, Hanamura I, Murakami H, Inoko A, Rahman ML, Hyodo T, Konishi H, Tsuzuki S, Hosokawa Y.

Cancer Sci. 2019 Jan;110(1):180-193. doi: 10.1111/cas.13871. Epub 2018 Dec 14.

17.

18F-FDG PET/CT in therapy response and in predicting responders or non-responders in malignant pleural mesothelioma patients, by using semi-quantitative mRECIST and EORTC criteria.

Niccoli Asabella A, Di Palo A, Altini C, Fanelli M, Ferrari C, Lavelli V, Ranieri G, Gadaleta CD, Rubini G.

Hell J Nucl Med. 2018 Sep-Dec;21(3):191-197. doi: 10.1967/s002449910904. Epub 2018 Nov 10.

18.

Multimodality treatment of malignant pleural mesothelioma.

Berzenji L, Van Schil P.

F1000Res. 2018 Oct 22;7. pii: F1000 Faculty Rev-1681. doi: 10.12688/f1000research.15796.1. eCollection 2018. Review.

19.

Apatinib for salvage treatment of advanced malignant pleural mesothelioma: A case report.

Du Z, Yu Y, Wu D, Zhang G, Wang Y, He L, Meng R.

Medicine (Baltimore). 2018 Nov;97(45):e13105. doi: 10.1097/MD.0000000000013105.

20.

Peritoneal Deciduoid Malignant Mesothelioma on 67Ga SPECT/CT.

Lai YC, Wu YC, Kao CH, Hsieh TC, Sun SS.

Clin Nucl Med. 2019 Feb;44(2):161-163. doi: 10.1097/RLU.0000000000002363.

PMID:
30394926

Supplemental Content

Loading ...
Support Center